BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 أبريل 2025 16:01:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

31 مارس 2025 16:10:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Leadership Transition

25 مارس 2025 19:00:00 بحسب Nasdaq GlobeNewswire

Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

24 مارس 2025 08:30:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

03 مارس 2025 08:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Unveil New Icovamenib Data at the 18th International Conference on Advanced Technologies & Treatments for Diabetes

27 فبراير 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

13 يناير 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

07 يناير 2025 09:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 يناير 2025 07:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

17 ديسمبر 2024 08:10:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

16 ديسمبر 2024 18:15:01 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

12 ديسمبر 2024 17:02:21 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

09 ديسمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia

06 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

02 ديسمبر 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

18 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 نوفمبر 2024 16:05:51 بحسب Nasdaq GlobeNewswire

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

30 أكتوبر 2024 16:00:48 بحسب Nasdaq GlobeNewswire

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights

29 أكتوبر 2024 16:46:08 بحسب Nasdaq GlobeNewswire

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219

21 أكتوبر 2024 09:00:29 بحسب Nasdaq GlobeNewswire